Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors

Inclusion Criteria

• •No age or gender limit, though minimal weight limitations for apheresis is about 15 - 20 Kg.
• •Both male and female of childbearing age entering the protocol must use a medically accepted form of birth control during the study, will be required to have a negative pregnancy test for female.
• •patients with atypical malignant brain tumor will be eligible.
• •Patients must have a Karnofsky performance score of at least 60%
• •patients may be maintained on glucocorticoid therapy at the lowest possible dose.
• •Baseline hematologic studies and chemistry profiles must meet the criteria.
• •Tumor specimen of adequate size to yield protein concentration in sufficient quantity.
• •Tumor-lysate peptide must be generated in sufficient quantity to pulse the APC's for vaccination.
• •Patient must have no prior sensitivity to the components of the dendritic cell vaccine.
• •Patient must agree to consider an autopsy in the event of death in an attempt to learn more concerning the nature of this treatment and tumor biology.
• •Patient must be capable of signing IRB approved Research Consent and Release of medical Records form.